Department of Transfusion Medicine and Hematology, C. Poma Hospital, Mantova, Italy.
Semin Thromb Hemost. 2012 Jul;38(5):447-53. doi: 10.1055/s-0032-1305779. Epub 2012 Jun 27.
Acquired coagulation inhibitors are antibodies that bind to coagulation factors and neutralize their activity or accelerate their clearance. Inhibitors occurring in patients with inherited deficiencies of coagulation factors are referred to as "alloantibodies," while those developing spontaneously in individuals with previously normal coagulation factor function are designated as "autoantibodies." The latter category includes inhibitors against coagulation factors I, II, V, VII, VIII (acquired hemophilia A), IX (acquired hemophilia B), X, XI, and XIII. This review will discuss the most important pathogenic, clinical, laboratory, and therapeutic aspects of the inhibitors of coagulation factors other than acquired hemophilia A, as this is reviewed separately within this issue of the journal.
获得性凝血抑制剂是指能与凝血因子结合并中和其活性或加速其清除的抗体。在遗传性凝血因子缺乏症患者中出现的抑制剂被称为“同种抗体”，而在先前凝血因子功能正常的个体中自发产生的抑制剂则被指定为“自身抗体”。后者包括针对凝血因子 I、II、V、VII、VIII（获得性血友病 A）、IX（获得性血友病 B）、X、XI 和 XIII 的抑制剂。本篇综述将讨论除获得性血友病 A 以外的其他凝血因子抑制剂的最重要的发病机制、临床、实验室和治疗方面，因为这在本期刊的单独一篇文章中进行了综述。
